Levy Raphi sold $220K of DRTS
Levy Raphi (Chief Financial Officer) sold 20,000 shares of Alpha Tau Medical Ltd. (DRTS) at $11.00 ($0.22M total) across 2 trades on 2026-06-25 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
This provides a fresh, primary-source datapoint on insider activity, but the 10b5-1 structure generally dampens the market’s inference about company outlook.
Market read
Traders may note the CFO’s scheduled selling, but it is unlikely to drive a fundamental repricing absent other catalysts.
What to watch
The filing doesn’t state motivations or future trading; without additional context (e.g., other insider buys/sells around the same period), signal strength is limited.
Background
The article is an SEC Form 4 insider transaction: CFO Levy Raphi sold 20,000 shares of Alpha Tau Medical Ltd. (DRTS) on 2026-06-25 under a pre-arranged 10b5-1 plan.
Ticker impact
Alpha Tau Medical CFO Levy Raphi sold 20,000 shares on 2026-06-25 at ~$11.0002 via a 10b5-1 plan, per Form 4.
Low likelihood of a sustained price move; any impact is likely short-lived and sentiment-driven.
The filing is a primary Form 4 disclosure and the transaction is explicitly tied to a pre-arranged 10b5-1 plan, which usually reduces interpretive weight versus discretionary selling.
Market effects
No sector-level implications; this is company-specific insider transaction disclosure.
None indicated; transaction is not tied to macro/regional events.
None indicated; no deal, guidance, or regulatory action mentioned.
Counterpoint
Because it’s a 10b5-1 plan, the sale may reflect scheduled liquidity needs rather than negative fundamentals; traders may ignore it for directional bets.
Key entities
- issuerAlpha Tau Medical Ltd.
Subject of the Form 4 insider sale disclosure.
- insiderLevy Raphi
Chief Financial Officer who sold shares under a 10b5-1 plan.
